Blog

Acadia Pharmaceutical has been litigating to keep out generics for its Parkinson’s Disease drug Nuplazid®.  Although Acadia initially sued five separate generics for infringement of multiple patents, all the generics settled-out except one, MSN Pharmaceuticals.  And in the case against MSN, only a single patent remains at issue (U.S. Patent No. 7,601,740).  MSN recently moved for summary judgment on the ground that the ‘740 patent is invalid for obviousness-type double patenting (ODP).  A recent precedential Federal Circuit decision, In Re: Cellect, LLC, addressed the ODP doctrine in detail.  How will Cellect affect Acadia’s defense against the last generic holdout for Nuplazid®?